Standout Papers

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozol... 2014 2026 2018 2022 1.4k
  1. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study (2014)
    Richard S. Finn, John Crown et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 11 from Science/Nature 111 standout
Sub-graph 1 of 16

Citing Papers

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
2024 Standout
20 intermediate papers

Works of Ravindranath Patel being referenced

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
2020
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Ravindranath Patel 1462 1374 575 14 1.8k
Anu Thummala 1401 1324 526 12 1.7k
Olga Burdaeva 1630 1563 621 27 2.0k
Kathy Puyana Theall 2049 1828 787 26 2.3k
Nawel Bourayou 2026 1797 723 23 2.3k
Han Koh 1883 2178 836 25 2.7k
Alex Pearson 795 893 528 16 1.4k
Yuan Liu 1308 1141 746 41 1.7k
Yuqiu Jiang 1357 1542 829 26 2.3k
Dylan Conklin 1064 1185 394 31 1.8k
Ondrej Kalous 939 1132 332 24 1.7k

All Works

Loading papers...

Rankless by CCL
2026